
Sign up to save your podcasts
Or
In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.
3.7
5353 ratings
In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.
131 Listeners
325 Listeners
161 Listeners
865 Listeners
496 Listeners
281 Listeners
3,336 Listeners
90 Listeners
138 Listeners
1,095 Listeners
39 Listeners
185 Listeners
349 Listeners
427 Listeners
37 Listeners